AbsTrACT background two recent randomised trials studied the benefit of mineralocorticoid receptor antagonists (Mras) in st-segment elevation myocardial infarction (steMi) irrespective or in absence of heart failure. the studies were both undersized to assess hard clinical endpoints. a pooled analysis was preplanned by the steering committees. Methods We conducted a prespecified meta-analysis of patient-level data of patients with steMi recruited in two multicentre superiority trials, randomised within 72 hours after symptom onset. Patients were allocated (1:1) to two Mra regimens: (1) an intravenous bolus of potassium canrenoate (200 mg) followed by oral spironolactone (25 mg once daily) versus standard therapy or (2) oral eplerenone (25-50 mg) versus placebo. the primary and key secondary outcomes, all-cause death and the composite of all-cause death or resuscitated sudden death, respectively, were assessed in the intention-to-treat population using a cox model stratified on the study identifier. results Patients were randomly assigned to receive (n=1118) or not the Mra regimen (n=1123). after a median follow-up time of 188 days, the primary and secondary outcomes occurred in 5 (0.4%) and 17 (1.5%) patients (adjusted hr (adjhr) 0.31, 95% ci 0.11 to 0.86, p=0.03) and 6 (0.5%) and 22 (2%) patients (adjhr 0.26, 95% ci 0.10 to 0.65, p=0.004) in the Mra and control groups, respectively. there were also trends towards lower rates of cardiovascular death (p=0.06) and ventricular fibrillation (p=0.08) in the Mra group. Conclusion Our analysis suggests that compared with standard therapy, Mra regimens are associated with a reduction of death and death or resuscitated sudden death in steMi.
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InTroduCTIon rationale
High aldosterone plasma levels early after myocardial infarction (MI) are associated with mortality, sudden cardiac death and heart failure. [1] [2] [3] [4] [5] Experimental studies have shown that early administration of mineralocorticoid receptor antagonist (MRA) after MI could improve myocardial healing and both electrical and structural remodelling. 6 7 Small-sized studies have also reported a benefit of MRAs, initiated early after MI in the prevention of left ventricular remodelling 8 9 and life-threatening arrhythmia. 10 11 MRAs spironolactone and eplerenone reduce mortality in the setting of congestive heart failure with reduced ejection fraction and MI complicated by left ventricular dysfunction and heart failure. [12] [13] [14] The 15 showed that eplerenone used within the first 24 hours of ST-segment elevation MI (STEMI) excluding patients with heart failure was safe and effective on a composite outcome mainly driven by the biological outcome of a lower plasma level of B-type natriuretic peptide. More recently, the Aldosterone Lethal effects Blockade in Acute myocardial infarction Treated with or without Reperfusion to improve Outcome and Survival at Six months follow-up (ALBATROSS, NCT 01059136) failed to demonstrate a benefit of a spironolactone-based MRA regimen in improving outcome in the general setting of STEMI or non-STEMI irrespective of heart failure, but suggested a potential significant reduction of rates of death by the MRA in the STEMI subgroup of patients (77% of the population). 16 Both ALBATROSS and REMINDER studies were undersized to detect a difference in rates of hard clinical outcomes. A pooled analysis of individual participant-level data was preplanned by the steering committees of the two trials prior to the end of the inclusion periods.
objectives
The aim of this pooled analysis of patient-level data was to investigate the effect of an MRA regimen initiated early after the onset of STEMI, irrespective or in absence of heart failure, on mortality and the composite of death or resuscitated sudden death.
MeThods study design and population
Our study used pooled individual patient-level data of the STEMI subgroup of ALBATROSS 16 and the total population of REMINDER 15 randomised trials. Both trials studied the efficacy of an MRA regimen in addition to standard therapy in comparison with either standard therapy alone or associated with a placebo. The designs of the studies are briefly depicted in online supplementary table 1. ALBATROSS-eligible and REMINDER-eligible patients were men and non-pregnant women Coronary artery disease presenting with STEMI within 72 and 24 hours of symptom onset, respectively. REMINDER included patients with STEMI only while ALBATROSS included patients with STEMI (n=1229) and non-STEMI (n=369) with a significant interaction between the presentation type and treatment with respect to mortality. Hence, only patients with STEMI of ALBATROSS trial were included in the present analysis. Other differences between ALBATROSS and REMINDER studies included the treatment (intravenous potassium canrenoate followed by oral spironolactone vs oral eplerenone), the timing of the randomisation with respect to symptom onset (within 24 vs within 72 hours) and the duration of follow-up (182±40 vs 317±218 days). Furthermore, to be included in REMINDER no sign of heart failure was to be present at randomisation while in ALBATROSS patients were included regardless of signs of heart failure. The comparison between the patients' characteristics of the two studies is reported in online supplementary table 2.
outcomes
The primary outcome of ALBATROSS trial was the composite of death, resuscitated cardiac arrest, significant ventricular arrhythmia, class IA indication 17 for implantable defibrillator, new or worsening heart failure over the period of 6 months following randomisation. The primary outcome of REMINDER trial was the composite of cardiovascular mortality, rehospitalisation or extended initial hospital stay for heart failure or sustained ventricular tachycardia or ventricular fibrillation, left ventricular ejection fraction ≤40% ≥1-month postrandomisation or high B-type natriuretic peptide (BNP) or NT-proBNP levels. 15 The primary efficacy outcome of the present study was mortality of any cause. As BNP was not measured in ALBA-TROSS and there were differences between definitions of events between the trials such as heart failure (requiring any treatment vs hospitalisation or emergency room visit) or sustained/significant ventricular tachycardia (requiring any treatment vs hospitalisation), any endpoint other than mortality was considered as a secondary endpoint. The key secondary efficacy outcome was the composite of death and resuscitated sudden death. Other secondary efficacy outcomes analysed included cardiovascular death, resuscitated cardiac death, ventricular fibrillation, any ventricular arrhythmia (ventricular tachycardia or fibrillation), stroke, implanted cardiac defibrillator, class IA 17 indication for defibrillators-whether implanted or not-and recurrent MIstudy-specific definitions. An independent committee adjudicated all outcomes in both trials.
Safety outcomes included hyperkalaemia >5.5 and >6 mmol/L at any time after randomisation and acute renal failure defined by an increase in estimated glomerular filtration rate (eGFR) of ≥25% in comparison with admission eGFR. For the present analysis, eGFR was calculated for all patients based on Cockroft-Gault method.
statistical analysis
All analyses used individual patient-level data of the pooled STEMI subgroup of ALBATROSS and the total population of REMINDER trials. The pooled analysis of the two patient populations was preplanned by the steering committees of the two trials. The full raw datasets were provided by the studies' organisers and analysed independently from the published data. All data were assessed within the two sets for completeness and coherence. No specific issue was observed.
A one-stage approach was used for the analysis. Data were compared between treatment arms using the Cochran-MantelHaenszel test and a two-way analysis of variance, both using the study identifier as the stratification variable. χ 2 test and Student's t-test were used for the comparison of the variables between the studies.
All efficacy endpoints were analysed as time-to-event outcomes using Cox models systematically stratified on the study identifier with a follow-up time of 188 days equal to the median follow-up time of the pooled data. Kaplan-Meier cumulative hazards curves were drawn for the comparison of the primary and key secondary outcomes between treatment groups. Safety endpoints were analysed as binary variables compared between treatment groups using a Cochran-Mantel-Haenszel test stratified on the study identifier.
Post hoc sensitivity analyses were performed for all efficacy endpoints using the Cox models stratified on the study identifier and adjusted on variables unequally distributed between the treatment arms with a p value threshold of <0.20.
Interstudy heterogeneity assessments were performed by the measurement of the interaction between the study identifier and the treatment arm using a Cox model for efficacy endpoints and a logistic regression model for safety endpoints without stratification.
Interaction between subgroups predefined in the two trials and treatment was tested using the Cox models stratified on the study identifier when data were available for both trials.
All tests had a two-sided significance level of 5% and were performed using R software, V.3.2.3 for Mac (R Foundation for Statistical Computing).
resulTs
A total of 2241 patients were randomly assigned to the MRA regimen (1118 patients) or control regimen (1123 patients).
Despite the differences between ALBATROSS and REMINDER trials (online supplementary table 1), the active and control groups were well balanced with respect to most baseline characteristics and treatment strategies (table 1) with the exception of significantly higher heart rate (p=0.02) and systolic blood pressure (p=0.02), as well as higher rates of Killip class ≥2 on admission in the control group (p=0.02). The standard of care for the index event included fibrinolysis in 189 (8.4%), primary percutaneous coronary intervention (PCI) in 1954 (87.2%), any PCI in 2060 (91.9%) and coronary artery bypass surgery in 41 (1.8%) patients.
As reported in table 2, after a median follow-up of 188 days (IQR 52 days), the primary outcome (figure 1) occurred in 5 (0.4%) and 17 (1.5%) patients in the active and control groups, respectively (HR 0.30, 95% CI 0.11 to 0.81; p=0.01 and adjusted HR (adjHR) 0.31, 95% CI 0.11 to 0.86; p=0.03). Two unadjudicated deaths reported as security events 389 and 528 days after randomisation in the control and the active groups of REMINDER trial, respectively, were not included in the analysis. All resuscitated sudden deaths were reported within the analysis time. The key secondary outcome of death or resuscitated sudden death (figure 2) occurred in 6 (0.5%) and 22 (2%) patients in the active and control groups, respectively (HR 0.27, 95% CI 0.11 to 0.67; p=0.002 and adjHR 0.26, 95% CI 0.10 to 0.65; p=0.004). There were also trends towards lower rates of death from cardiovascular causes (p=0.06) and ventricular fibrillation (p=0.08) in the active group. Other assessed efficacy endpoints did not differ between the two groups. The two trials were different with respect to the rates of the primary and secondary key outcomes as well as several other outcomes (online supplementary table  3 ). However, with the exception of a trend (p=0.06) towards a heterogeneity in rates of recurrent MI, no significant interstudy heterogeneity was detected. The results were consistent among all subgroups with respect to the primary and secondary key outcomes (online supplementary figure). HR could not be calculated in the patient subgroups with a Killip class ≥2 in the active arms, as well as all patients with a Global Registry of Acute Coronary Events (GRACE) score <109 because of absence of any primary or secondary key outcome. HR could also not be calculated for death in patients <65 because of absence of event in the active arm.
Hyperkalaemia >5.5 mmol/L occurred in 37 (3.3%) and 20 (1.8%) patients in the active and control groups, respectively (stratified OR 1.89; 95% CI 1.09 to 3.29, p=0.03) while rates of hyperkalaemia >6 mmol/L and acute renal failure were not significantly different between the two groups. A trend towards (p=0.09) and a significant interstudy heterogeneity (p=0.04) were detected with respect to the hyperkalaemia >5.5 and 6 mmol/L outcomes.
dIsCussIon
Our analysis based on the pooled patient-level data of the two recent randomised trials addressing the question of early MRA blockade in low-risk STEMI shows reduced rates of death compared with standard therapy. Although the subgroup analysis should be considered as only exploratory, it suggests a consistent effect of the treatment. MRA blockade appears to be associated with reduced risks of all-cause mortality and the composite of death or resuscitated sudden cardiac death. However, the analysis failed to show a benefit with respect to other endpoints including heart failure or ventricular arrhythmia. Rates of hyperkalaemia >5.5 mmol/L were significantly higher among patients treated with MRA. Experimental studies have shown that the early use of MRA after MI reduces left ventricular expansion and extensive fibrosis by antagonising activation of the mineralocorticoid receptor by aldosterone and cortisol. 6 18 19 The clinical benefits of MRA have been extensively demonstrated in heart failure irrespective of its ischaemic or non-ischaemic origin. 12 13 MRA use is also associated with a reduction of mortality in patients with heart failure and reduced systolic ventricular function after MI.
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14 Thus, the addition of MRAs to beta-blockers and ACE inhibitors has been highly recommended [20] [21] [22] in patients with heart failure and reduced left ventricular function irrespective of the aetiology of heart failure.
In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) 15 eplerenone was initiated 3-14 days after the onset of MI complicated by heart failure and reduced left ventricular function. The benefit observed was apparently driven by the group of patients treated earlier (ie, 3-7 days). 23 This finding is consistent with other studies reporting high aldosterone plasma levels early after MI 24 25 and the relationship of these levels with clinical outcomes. [1] [2] [3] REMINDER study recruited low-risk patients with STEMI with no heart failure at admission and very low-mortality rates. Although REMINDER showed a benefit of eplerenone over placebo, the benefit was driven by the B-type natriuretic peptide levels with only non-significant trends on clinical outcomes. 15 ALBATROSS trial recruited a broader STEMI population at higher risk as compared with REMINDER. ALBATROSS STEMI population included all comers presenting for primary PCI, few with heart failure (6.7%), with significantly higher admission GRACE scores but also more contemporary and optimal treatment as compared with REMINDER. Although the study failed to show the benefit of MRAs on the primary outcome, it highlighted a significant signal in favour of an MRA effect on mortality in STEMI. The present pooled analysis includes a relatively young and low-to-intermediate risk STEMI population (mean GRACE score 140) treated optimally with very high rates of revascularisation and optimal medical therapy. The mortality reduction with MRAs in addition to an optimal management in such a low-risk population should not be neglected. The previously mentioned preclinical and clinical data, the reduction of mortality in the setting of chronic heart failure or post-MI heart failure as well as the strength of the association support the plausibility of an MRA effect on mortality in the setting of STEMI. The early blunting of biological effects of MR activation after acute coronary artery occlusion 6 7 18 may lead to a favourable effect in STEMI through the untriggering of the neurohormonal activation and the subsequent post-MI fibrosis and remodelling both leading to higher risk of death.
A recently published study-level meta-analysis of 11 randomised trials showed also the benefit of MRAs on mortality. 26 The study included patients with STEMI and non-STEMI, with heart failure as an inclusion criteria or not. However, the benefit of the MRAs was driven by studies that included patients with heart failure. Compared with the latter study, our patient-level analysis pooling only patients with STEMI, without heart failure as an inclusion criteria and with a more adequate univariable and adjusted analysis of censored data may be considered as more sensitive in detecting differences between groups.
Interestingly, the MRA-related reduction of mortality found in our study was not associated with a concordant significant reduction of major ventricular arrhythmia or heart failure, although both events occurred numerically less in the active treatment group.
Sustained ventricular tachycardia or fibrillation have been reported to occur in 5.2% of patients after primary PCI essentially in the first 48 hours in the relatively recent analysis of the Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction randomised trial. 27 In the latter study, such events did not portend decreased survival. The rates of ventricular tachycardia or fibrillation were approximately 4% in the pooled population of our analysis, with a difference between rates in ALBATROSS (7.2%) and REMINDER trials (0.4%). Such a difference is likely to be due to the difference of the definitions of ventricular tachycardia (requiring hospitalisation) in REMINDER but also due to a more selected patient population without heart failure at admission, with preserved ejection fraction and with extremely low event rates, that is, death, heart failure, indication for implantable cardioversion device (ICD). The absence of effect on rates of ventricular arrhythmia in our study is not in contradiction with a possible MRA effect on mortality. Concordant with our study, in both Randomized Aldosterone Evaluation Study 12 and EPHESUS 14 trials, mortality was reduced with MRA despite the absence of effect on the rates of ventricular arrhythmia. Moreover, in concordance with the above-mentioned study, 27 most ventricular tachycardia were reported within only 48 hours after randomisation and such events may not impact mortality. Finally ventricular arrhythmia suppression after MI is known not to improve survival. 28 Considering the trend towards a reduction of rates of ventricular fibrillation but not ventricular tachycardia in our analysis, it is plausible that MRAs may reduce the rates of lethal arrhythmia, or prevent the fatal issue of arrhythmia without affecting the frequency of post-STEMI arrhythmia in general.
The global rate of hospitalisation for heart failure (4.4%) in a recent multicentre real-life cohort of patients with STEMI undergoing primary PCI 29 was higher than in REMINDER (1.4%) but lower than in ALBATROSS (6.3%). The differences in study definitions, the low-risk populations and the short durations of follow-up could explain the absence of detectable MRA effect on heart failure in the current analysis.
Our analysis also highlights the relative safety of the MRA regimens used in the studies. Although the rates of hyperkalaemia >5.5 mmol/L were higher in the MRA group than in the control group, they remained lower than what has been previously reported 14 15 and the rates of hyperkalaemia >6 mmol/L and acute renal failure were not different between treatment groups. However, the results on hyperkalaemia should be considered with great precaution because of a significant interstudy heterogeneity.
Our analysis has limitations inherent to its design pooling data from different studies with different designs and different active treatments. However, a class effect is very likely between the drugs and the stratified and adjusted analyses as well as absence of detected interstudy heterogeneity may minimise the risk of bias. Furthermore, event rates remained low and event definitions were different for ventricular tachycardia and heart failure. Nevertheless with respect to the primary and the key secondary outcomes of our study-death and death or resuscitated sudden death-the analysis may be considered as robust. The adjusted analysis should be interpreted with the consideration of low event rates, especially with respect to mortality. However, the similar magnitude of effects and their CIs between the unadjusted and adjusted analyses supports the robustness of the findings. The subgroup analysis should be considered with great precaution because of the risk of multiple testing with low event rates. Whether the benefit of MRA may interact with the infarct location or the culprit vessel could not be assessed by our study because of lack of data.
Although the present report is the largest experience in STEMI outside of the scope of heart failure, it may lack power to detect differences between several studied outcomes. Larger and specifically designed studies are needed to assess such outcomes.
ConClusIons
Our analysis based on pooled patient-level data from two randomised trials suggests a significant reduction of death and death or resuscitated sudden death associated with MRA regimens given early after low-risk STEMI. Despite strong recommendations based on robust clinical evidence in the setting of heart failure, MRAs are still underused in routine clinical practice. Our data on both efficacy and safety of MRAs may contribute to extend the use of these life-saving and low-cost drugs. Although our study seems robust with respect to its primary outcome, the low event rates highlight the need for more studies adequately sized and specifically designed to confirm the potentially major clinical benefit associated with low-cost treatments.
Coronary artery disease Key messages
What is already known on this subject? ► Mineralocorticoid receptor antagonists (MRAs) reduce mortality in the setting of myocardial infarction complicated by heart failure.
What might this study add?
► The study shows that regardless of heart failure, MRAs reduce mortality in the setting of ST-segment elevation myocardial infarction (STEMI), in addition to optimal treatment.
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